UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 29, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________ Commission File Number 001-36820 ® Medtronic plc (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State of incorporation) (I.R.S. ...

Medtronic plc (NYSE:MDT) Q1 2023 Earnings Conference Call August 23, 2022 8:00 AM ET Company Participants Ryan Weispfenning - VP and Head, IR Geoff Martha - Chairman and CEO Karen Parkhill - CFO Sean Salmon - EVP and President, Cardiovascular Portfolio Bob White - EVP and President, Medical Surgical Portfolio Brett Wall - EVP and President, Neuroscience Portfolio Que Dallara - EVP and President, Diabetes Operating Unit Conference Call Participants Robbie Marcus - JPMorgan Vijay Kumar - Evercore ISI Travis S ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 29, 2022. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________ Commission File No. 1-36820 ® Medtronic plc (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State or other ...

Medtronic plc (NYSE:MDT) Conference Call Summary Company Overview - **Company**: Medtronic plc - **Event**: Goldman Sachs Global Healthcare Conference Call - **Date**: June 14, 2022 - **Participants**: Geoff Martha (Chairman & CEO), Amit Hazan (Goldman Sachs Medical Technology Analyst) Key Points Industry Context - The healthcare industry, particularly medical technology, has faced significant challenges due to COVID-19 and supply chain disruptions [4][5][6] - Medtronic has played a critical role in responding to the pandemic, particularly with ventilators [4] Supply Chain Challenges - Medtronic experienced acute supply chain issues, particularly with semi chips and resins affecting their Energy business and packaging [7][8] - A supplier explosion caused significant disruptions in the Surgical Innovations business [8] - Supply chain issues are expected to improve, particularly in the second half of the fiscal year [9] - The company is implementing structural changes to enhance supply chain resiliency, moving from a fragmented approach to a centralized model [11][12][14] Financial Guidance and Revenue Expectations - Medtronic is guiding for 4% to 5% revenue growth for the fiscal year, despite challenges in the previous quarters [22][24] - The company anticipates easier comparisons in the second half of the fiscal year due to lower bases from the previous year [25] - Key product launches are expected to drive growth, including new TAVR and EV ICD products [26] Research and Development (R&D) - Medtronic aims to increase R&D spending to outpace sales growth, focusing on higher-growth opportunities [28] - The company is committed to improving R&D productivity and has streamlined operations to allow for increased investment [29] Operating Margins - Medtronic is targeting a return to pre-COVID operating margins of around 28% [30][32] - The company is focused on achieving 5% top-line growth and 8% EPS growth, alongside a growing dividend [32][33] Product Development and Market Position - The surgical robot is expected to see significant growth, with positive feedback from international markets [34][36] - Medtronic is optimistic about the diabetes segment, with the 780G system showing promising results in trials [41][43] - The company is also focused on the renal denervation (RDN) market, with ongoing trials expected to yield positive results [48][49] Market Dynamics in China - Short-term challenges include navigating COVID lockdowns and pricing pressures, but long-term growth in China is still anticipated [53][54] - Medtronic acknowledges increased risks in the Chinese market due to geopolitical factors but remains bullish on investment opportunities [55] Capital Allocation and Portfolio Management - Medtronic is conducting a deep dive into its portfolio to ensure capital is allocated to higher-growth areas [57] - Ongoing evaluations may lead to divestitures or restructuring within the portfolio [57] Additional Insights - The company is adapting to a new normal in supply chain management, balancing efficiency with resiliency [11][14] - Medtronic's strategy includes leveraging acquisitions and partnerships to enhance R&D capabilities [29] - The focus on integrated insulin delivery systems positions Medtronic favorably in the diabetes market [44][46] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Medtronic's response to current challenges and its plans for future growth.

Medtronic plc (NYSE:MDT) Q4 2022 Earnings Conference Call May 26, 2022 8:00 AM ET Company Participants Ryan Weispfenning - Head of IR Geoff Martha - CEO Karen Parkhill - CFO Brad Lerman - SVP, General Counsel, Corporate Secretary Bob White - EVP and President of the Medical Surgical Portfolio Sean Salmon - EVP and President of the Cardiovascular Portfolio Conference Call Participants Vijay Kumar - Evercore ISI Travis Steed - Bank of America Merrill Lynch Larry Biegelsen - Wells Fargo Shagun Singh - RBC Ca ...

Medtronic plc (NYSE:MDT) 42nd Annual Cowen Health Care Conference Call Summary Company Overview - **Company**: Medtronic plc - **Event**: 42nd Annual Cowen Health Care Conference Call - **Date**: March 7, 2022 - **Participants**: - Karen Parkhill - Executive Vice President and Chief Financial Officer - Josh Jennings - Cowen & Company Key Points Industry and Market Trends - **Fiscal Q4 Trends**: February was expected to be the lightest month, with modest underlying procedure acceleration. Greater acceleration is anticipated in March and April [4][3] - **Impact of Russia/Ukraine Conflict**: Medtronic has minimal exposure, with revenue from these regions being less than 1% of total revenue. No manufacturing or direct material suppliers are located in these countries [5] Financial Performance and Guidance - **Supply Chain and Inflation**: No changes in supply chain guidance since the fiscal third quarter earnings call. Inflationary pressures are expected to continue into FY 2023, impacting EPS growth [6][32] - **EPS Growth Expectations**: FY 2023 is expected to be challenging, with EPS growth anticipated but not exceeding revenue growth. Currency fluctuations and acquisition dilution are expected to impact EPS by a few hundred basis points [33][32] Product Development and Regulatory Updates - **Diabetes Franchise**: Ongoing discussions with the FDA regarding the warning letter and the approval of key diabetes products (780G and Guardian 4). Progress is being made on remediation efforts [9][11] - **Renal Denervation**: Confidence in the approval of renal denervation therapy based on previous studies. The ON MED trial results are expected to be shared at a major cardiovascular meeting [16][20] - **Hugo Surgical System**: Positive feedback from surgeons on the Hugo system's features. The system is currently in limited market release, with high demand and ongoing data collection for regulatory filings [21][23] Strategic Initiatives - **Portfolio Review**: Medtronic is intensively reviewing its portfolio to optimize business units and drive sustainable revenue growth. Decisions regarding potential divestitures or spinouts are expected within the fiscal 2023 timeframe [36][40] - **Macro Challenges**: Ongoing challenges include staffing shortages, supply chain issues (particularly in semiconductors and resins), and inflation. These factors are expected to persist into FY 2023 and potentially FY 2024 [43][46] Acquisitions - **Intersect ENT Acquisition**: The acquisition is progressing well, with expectations for closing soon [48] Additional Insights - **Long-term Growth Commitment**: Medtronic remains committed to its long-range plan, with expectations for a return to organic revenue growth post FY 2023 [35][34] - **Investment in R&D**: Continued investment in R&D is crucial for future growth, despite current economic challenges [33][32] This summary encapsulates the key discussions and insights from the Medtronic conference call, highlighting the company's strategic direction, financial outlook, and product development efforts.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 28, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________ Commission File Number 001-36820 ® Medtronic plc (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State of incorporation) (I.R ...

Medtronic plc (NYSE:MDT) Q3 2022 Earnings Conference Call February 22, 2022 8:00 AM ET Company Participants Ryan Weispfenning - Vice President and Head, Investor Relations Geoff Martha - Chairman and Chief Executive Officer Karen Parkhill - Chief Financial Officer Sean Salmon - Executive Vice President and President, Cardiovascular and Diabetes Bob White - Executive Vice President and President, Medical Surgical Brett Wall - Executive Vice President and President, Neuroscience Conference Call Participants R ...